Immunic Unveils New Data Strengthening Vidofludimus Calcium's Case for Progressive MS
Event summary
- Immunic presented three posters at the 2026 CMSC Annual Meeting, including a late-breaking analysis introducing a novel statistical approach for measuring disability changes in progressive MS.
- The new Confirmed Disability Change (CDC) endpoint captures both worsening and improvement, favoring vidofludimus calcium over placebo across multiple models.
- Patient-reported outcomes showed no negative impact on mood and a favorable safety profile with comparable adverse events between vidofludimus calcium and placebo.
- Over 3,400 individuals have been exposed to vidofludimus calcium, demonstrating a favorable pharmacokinetic, safety, and tolerability profile.
The big picture
Immunic's latest data reinforces vidofludimus calcium's potential in progressive MS, a segment with significant unmet needs and limited treatment options. The introduction of the CDC endpoint could set a new standard for measuring disability trajectories, while the favorable safety and tolerability profile supports its continued development. With phase 3 trials for relapsing MS ongoing and top-line data expected by year-end, Immunic is positioning itself as a key player in the neurological disease space.
What we're watching
- Clinical Validation
- Whether the novel CDC endpoint will gain broader adoption in progressive MS trials, potentially improving statistical power and treatment benefit capture.
- Regulatory Pathway
- The feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive MS, following the promising phase 2 CALLIPER trial results.
- Market Differentiation
- How Immunic positions vidofludimus calcium against existing and emerging therapies for progressive MS, leveraging its unique neuroprotective, anti-inflammatory, and anti-viral effects.
Related topics